Cargando…
Is treatment with interferon-α effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions
The first analysis of the MRC RE01 trial in metastatic renal carcinoma identified a 28% reduction in the hazard of death for patients treated with interferon-α compared with medroxyprogesterone acetate (MPA). No subgroup was identified in which treatment with interferon-α was more or less effective...
Autores principales: | Royston, P, Sauerbrei, W, Ritchie, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410187/ https://www.ncbi.nlm.nih.gov/pubmed/14970855 http://dx.doi.org/10.1038/sj.bjc.6601622 |
Ejemplares similares
-
An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma
por: Royston, P, et al.
Publicado: (2006) -
Metastatic renal carcinoma comprehensive prognostic system
por: Atzpodien, J, et al.
Publicado: (2003) -
Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials
por: Sauerbrei, Willi, et al.
Publicado: (2022) -
Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
por: Yang, S, et al.
Publicado: (2010) -
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010)